Abstract. Tamoxifen inhibits transmembrane currents of the Kir2.x inward rectifier potassium channels by interfering with the interaction of the channels with membrane phosphatidylinositol 4,5-bisphosphate (PIP 2 ). We tested the hypothesis that Kir channels with low affinity for PIP 2 , like the adenosine triphosphate (ATP)-sensitive K + channel (K ATP ) and acetylcholine (ACh)-activated K + channel (K ACh ), have at least the same sensitivity to tamoxifen as Kir2.3. We investigated the effects of tamoxifen (0.1 -10 μM) on Kir6.2/SUR2A (K ATP ) and Kir3.1/3.4 (K ACh ) channels expressed in HEK-293 cells and ATP-sensitive K + current (I KATP ) and ACh-activated K + current (I KACh ) in feline atrial myocytes. The onset of tamoxifen inhibition of both I KATP and I KACh was slow (T 1/2 approximately 3.5 min) and concentration-dependent but voltage-independent. The time course and degree of inhibition was independent of external or internal drug application. Tamoxifen interacts with the pore forming subunit, Kir6.2, rather than with the SUR subunit. The inhibitory potency of tamoxifen on the Kir6.2/SUR2A channel was decreased by the mutation (C166S) on Kir6.2 and in the continuous presence of PIP 2 . In atrial myocytes, the mechanism and potency of the effects of tamoxifen on K ATP and K ACh channels were comparable to those in HEK-293 cells. These data suggest that, similar to its effects on Kir2.x currents, tamoxifen inhibits K ATP and K ACh currents by interfering with the interaction between the channel and PIP 2 .
Introduction
Tamoxifen is widely used in the treatment and prevention of breast cancer in both pre-and post-menopausal women. The anti-tumoral character of this compound is attributed mainly to its anti-estrogenic activity via competitive binding to the estrogen receptor, blocking the action of estradiol (1) . Tamoxifen has been shown also to have inhibitory effects on several potassium conductances in cardiac tissue, including I K1 , I to , I sus , and I Kr (2 -6) . Recently, we found that tamoxifen at clinically relevant concentrations reduces currents of several Kir2.x inward rectifier potassium channels in an heterologous expression system and I K1 in feline cardiac myocytes (7) . The order of tamoxifen potency was Kir2.3 > Kir2.1 = Kir2.2. Evidence suggested that the inhibitory effects of tamoxifen on Kir2.x channels were due to interference with the interaction of the channels with membrane phosphatidylinositol 4,5-bisphosphate (PIP 2 ). Inhibition of Kir2.3 currents was significantly reduced by a single point mutation (I213L), which enhances its interaction with membrane PIP 2 . In addition, in excised inside-out patches pretreated with PIP 2 , the effect of tamoxifen on Kir2.1 and Kir2.3 currents was significantly decreased. Similar results on Kir2.3 channels were found with the antihistamines mepyramine and diphenhydramine (8) .
A common feature of Kir channels is that they all require PIP 2 to maintain their activity (9) . Characteristics of membrane PIP 2 -Kir channel interactions determine the sensitivity of Kir to many regulatory factors (10) . The Kir6.2 and Kir3.1/3.4 subunits, which form the pore domains of the adenosine triphosphate (ATP)-sensitive K + channel (K ATP ) (11 -13) and acetylcholine (ACh)-activated K + channel (K ACh ) (14) , respectively, have weak interactions with PIP 2 (10) . Therefore, according to our finding that tamoxifen inhibited the Kir2.x channels by interfering with the channel-membrane PIP 2 interaction, the drug may produce inhibition of the K ATP and K ACh channels with a potency at least similar to that on Kir2.3. To our knowledge no reports exist about the effect of tamoxifen on Kir6.2/SUR2A or Kir3.1/3.4 channels.
The cardiac K ATP channel is a complex of two proteins: a pore forming subunit, Kir6.2, and the sulfonylurea receptor, SUR2A (11 -13) . We have explored whether tamoxifen interacts with SUR2A or with Kir6.2, by studying the effect of tamoxifen on the Kir subunit in the absence of the sulfonylurea receptor. However, Kir6.2 alone does not express functional K ATP currents (15 -17) . Therefore, we have examined the effect of tamoxifen on a truncated form of Kir6.2 (Kir6.2ΔC36) in which the last 36 amino acids of the C-terminal domain have been deleted. This channel is able to express significant current in the absence of SUR2A (17) . On the other hand, the Kir6.2 (C166S) mutation markedly increases the channel open probability by reducing the percentage of time the channel spends in a long closed state (18) . Published evidence suggests that the mutation C166S enhances the PIP 2 -channel interaction (18) . In the present work, we studied the effects of tamoxifen on Kir6.2/ SUR2A, Kir6.2 mutant C166S/SUR2A, and the Kir6.2ΔC36 channels, expressed in HEK-293 cells. We have also investigated the effect of the drug on ATPsensitive K + current (I KATP ) in feline atrial myocytes. We found that tamoxifen inhibited Kir6.2/SUR2A channel current and its corresponding current in native cells.
K ACh is a heterotetramer comprised of Kir3.1 and Kir3. 4 (14) that regulates cardiac atrial electrophysiology. Here, we have also examined the effects of tamoxifen on Kir3.1/3.4 channels expressed in HEK-293 cells and ACh-activated K + current (I KACh ) in atrial myocytes. -and spermine-free. The application of 30 mM K 2 ATP was sufficient to abolish any detectable current through Kir6.2 channels, and off-line subtraction of 30 mM K 2 ATP currents was used to subtract endogenous currents.
Materials and Methods

Molecular biology and cell transfection
Current recordings in cardiac myocytes
Experiments were conducted following the guidelines for the humane use of laboratory animals of the Ethics Committee of the University of Colima (Mexico). Single left atrial myocytes were obtained from adult cats as previously described (20) . The hearts were mounted on a Langendorff apparatus and perfused for 5 min with nor-mal Tyrode's solution and then switched to a nominally calcium-free solution for an additional 5 min. Thereafter, the hearts were perfused for 30 min with a zero-calcium solution containing 0.33 mg/ml type-I collagenase (Sigma-Aldrich, St. Louis, MO, USA) and 0.033 mg/ml protease type-XIV (Sigma-Aldrich). The enzymes were washed out by perfusion with a high-potassium, lowchloride saline (KB medium) for 5 min. The left atrium was dissected away from the rest of the heart, placed in different beakers, and cut into small pieces. Single cells were maintained in KB medium at 4°C for up to 10 h before use in electrophysiological experiments.
The Tyrode's solution had the following composition 118 mM NaCl, 24 mM NaHCO 3 Macroscopic currents were recorded in the whole-cell configuration of the patch-clamp technique (19) , using an Axopatch-200B amplifier (Molecular Devices). Data acquisition and command potentials were controlled by pClamp 9.0 software (Molecular Devices). Patch pipettes with a resistance of 1 -2 MΩ were made from borosilicate capillary glass (WPI). The external solution used to record K ATP membrane currents in isolated myocytes had the following composition: 136 mM NaCl, 5.4 mM KCl, 0.1 mM CaCl 2 , 0.5 mM CoCl 2 , 1 mM MgCl 2 , 10 mM HEPES, and 11 mM glucose, pH adjusted to 7.4 with NaOH. The pipette solution had the following composition: 80 mM potassium aspartate, 10 mM KH 2 PO 4 , 1 mM MgSO 4 , 40 mM KCl, 5 mM HEPES, 10 mM EGTA, 0.2 mM GTP-Na, 1 mM ATP-Mg, and 5 mM phosphocreatine, adjusted to pH 7.25 with KOH.
The external solution used to record K ACh membrane current in isolated myocytes had the following composition: 136 mM NaCl, 4 mM KCl, 0.5 mM CaCl 2 , 2 mM CoCl 2 , 1 mM MgCl 2 , 10 mM HEPES, and 11 mM glucose, pH adjusted to 7.4 with NaOH. The pipette solution had the following composition: 80 mM potassium aspartate, 10 mM KH 2 PO 4 , 1 mM MgSO 4 , 40 mM KCl, 5 mM HEPES, 10 mM EGTA, 0.2 mM GTP-Na, 3 ATP-Na 2 , and 5 mM phosphocreatine, pH 7.25 KOH. All drugs were applied in rapid perfusion using the corresponding external solution.
Macroscopic currents (whole-cell configuration) of Kir6.2/SUR2A and I KATP were induced by the K ATPchannel opener pinacidil (100 μM). The effect of tamoxifen was evaluated in the continuous presence of 100 μM pinacidil at steady state. The K ATP -channel blocker glibenclamide (10 μM) completely blocked the pinacidil-induced current and was used to dissect out Kir6.2/SUR2A and I KATP currents. Macroscopic I KACh , activated by the muscarinic agonist carbachol (CCh) at a concentration of 300 nM, was recorded in the whole-cell configuration. The current was activated by application of CCh alone during 30 s, and washed out. Then, tamoxifen at different concentrations were applied during 8 -10 min, followed by a second application of CCh for 30 s in the continuous presence of tamoxifen.
Drugs
Tamoxifen (Sigma-Aldrich) was dissolved in ethanol and stored at −20°C. Aliquots of the stock solution were diluted to the desired concentration with the bath solution. HEK-293 cells and myocytes were exposed to drug solutions until steady-state effects were achieved. The effects of the drugs were measured 8 -10 min after bath application in whole-cell experiments and inside-out patches. To determine the concentration-effect relationships, a single cell was exposed to only one concentration of the drug. Pinacidil and glibenclamide were dissolved in DMSO (final concentration of solvent 0.1%). CCh was dissolved directly in the external solution.
Data analysis
Patch-clamp data were processed using Clampfit 9.0 (Molecular Devices) and then analyzed in Origin 7 (Origin Lab, Northampton, MA, USA). Data are presented as the mean ± S.E.M. (n = number of cells). For the wholecell experiments, currents were normalized to the current recorded at −110 mV (Kir6.2/SUR2A) or −20 mV (I KATP ) or −120 mV (I KACh ) under control conditions. For the inside-out experiments, currents were normalized to the current recorded at −80 mV under control conditions. The fractional block of current (f) was plotted as a func- 
Statistics
Statistical analyses were performed using the Statistica software package, version 10.0 (Tulsa, OK, USA).
Concentration-response data were tested for significance by Student's t-test, applying Bonferroni's correction for multiple comparisons. Student's t-test was applied to compare individual data sets. A two-tailed probability value of less than 0.05 was considered statistically significant.
Results
Tamoxifen reduces current through K ATP channels
The effects of tamoxifen on Kir6.2/SUR2A WT channels were first studied on macroscopic currents recorded in inside-out excised membrane patches in transfected HEK-293 cells. Voltage ramps of 3 s were applied from −80 to +60 mV every 20 s. Test solutions were applied to the intracellular membrane surface. Under control conditions, current was almost linear in the range of potentials tested (Fig. 1A) . Tamoxifen at 0.3 μM significantly decreased current amplitude, similarly throughout Control record (trace C), 100 μM pinacidil (trace Pina), and 0.3 μM tamoxifen in the presence of pinacidil (Pina + T). The shown traces correspond to the current sensitive to 10 μM glibenclamide. D: Concentration-response curves constructed from currents measured at −80 mV in inside-out and at −110 mV in whole-cell configuration. The IC50 of tamoxifen on Kir6.2/SUR2A was 0.23 ± 0.04 μM (n = 8) and that on Kir6.2ΔC36 was 0.38 ± 0.06 μM (n = 7), both in the inside-out configuration, and that on Kir6.2/SUR2A was 0.33 ± 0.07 μM (n = 5) in the whole-cell configuration. Data were not significantly different (P > 0.05). All figures show the current elicited by the ramp. The holding current and the first voltage step are not shown (see protocol in the inset). E: Voltage-dependence of the inhibitory effect of 0.3 μM tamoxifen on Kir6.2/SUR2A in whole-cell and inside-out configurations and on Kir6.2ΔC36 in the inside-out configuration. Data were obtained from similar records to those shown in panels A -C (n = 6, n = 5, and n = 5, respectively). F: Time courses of the inhibitory effect of 0.3 μM tamoxifen on Kir6.2/SUR2A, in both whole-cell and inside-out configurations, measured at −110 and −80 mV, respectively, and of the mutant Kir6.2ΔC36 in the inside-out configuration measured at −80 mV. C the whole range of voltages studied (Fig. 1E) . The time course of tamoxifen inhibition on Kir6.2/SUR2A current measured at −80 mV is slow (Fig. 1F) , with a T 1/2 of 216 ± 47 s (n = 5).
To determine whether the site at which tamoxifen interacts lies on Kir6.2 or on SUR2A, we tested the drug on a truncated form of Kir6.2 (Kir6.2ΔC36) that expresses functional channels in the absence of SUR2A. Figure 1B shows that Kir6.2ΔC36 current was inhibited by 0.3 μM tamoxifen in a voltage-independent manner (Fig. 1E) and with slow time course (T 1/2 of 175 ± 20 s; n = 5) similar to Kir6.2/SUR2A current (Fig. 1F) . This result indicates that the inhibitory effect of tamoxifen is not mediated by SUR2A and further suggests that the drug interacts either with Kir6.2ΔC36 or possibly with a third molecule, endogenously present in HEK293 plasma membrane, that modulates the activity of Kir6.2ΔC36.
Concentration-response curves for the inhibitory effects of tamoxifen on currents measured at −80 mV in both channels are shown in Fig. 1D . The IC 50 of tamoxifen for Kir6.2/SUR2A (0.23 ± 0.04 μM; n = 8 cells) and Kir6.2ΔC36 (0.38 ± 0.06 μM; n = 7 cells) were not significantly different.
Tamoxifen inhibits Kir6.2/SUR2A current equally after internal and external membrane application
The effect of tamoxifen on Kir6.2/SUR2A channel was also studied in the whole-cell configuration. Voltage ramps of 3 s were applied from −110 to −20 mV every 20 s, in the presence of the K ATP channel opener pinacidil (100 μM) (Fig. 1C) . Tamoxifen at 0.3 μM significantly decreased current amplitude in a voltage-independent manner (Fig. 1E) . The time course of inhibition was slow in the whole-cell configuration experiments (Fig. 1F) , with a T 1/2 = 187 ± 19 s (n = 4), which was not significantly different from the T 1/2 obtained in the inside-out configuration (216 ± 47 s). Thus, the slow onset of inhibition from either membrane surface suggests that tamoxifen must incorporate into the lipid membrane to exert its inhibitory effect. The concentration-effect relationship is shown in Fig. 1D ; the IC 50 of 0.33 ± 0.07 μM (n = 5) was within the same range as the IC 50 obtained in the inside-out configuration. Figure 2A shows the effects of tamoxifen (3 μM) on currents flowing through Kir6.2C166S/SUR2A mutant channels. Tamoxifen decreased current amplitude in a voltage-independent manner. However, the potency of inhibition was reduced approximately 10-fold by the point mutation. The IC 50 for tamoxifen on the Kir6.2C166S/SUR2A mutant was 1.98 ± 0.22 μM, n = 5 cells (Fig. 2B) . To determine whether there is a relationship between the tamoxifen effects and PIP 2 , exogenous PIP 2 was added and the effects compared to those of tamoxifen in the absence of PIP 2 . Figure 2C shows representative Kir6.2/SUR2A current traces in the presence of 1 μM tamoxifen alone (Fig. 2C: a) and together with 30 μM PIP 2 ( Fig. 2C: b) , superimposed on their respective controls. PIP 2 significantly decreased the inhibitory effects of tamoxifen on Kir6.2/SUR2A (Fig. 2D) .
Tamoxifen interferes with Kir6.2/SUR2A channels-PIP 2 interaction
Tamoxifen inhibits I KATP in feline atrial myocytes
The effects of tamoxifen on feline atrial myocytes were studied in the whole-cell configuration. Voltage ramps of 3 s were applied from −120 to −20 mV every 20 s, in the presence of the K ATP channel-opener pinacidil (100 μM). The current showed little inward rectification, which is typical of K ATP channels. Tamoxifen at 0.3 μM significantly decreased current amplitude (Fig. 3A) , in a voltage-independent manner. The concentration-response curve for the inhibitory effects of tamoxifen on I KATP measured at −20 mV is shown in Fig. 3B , resulting an IC 50 of 0.22 ± 0.04 μM (n = 5). Figure 4A shows the effects of 1 μM tamoxifen on constitutively activated Kir3. Figure 4C shows the effect of 0.3 μM tamoxifen on I KACh activated by 300 nM CCh in a feline atrial myocyte. Figure 4D shows the concentration-response curve for the inhibitory effects of tamoxifen on I KACh activated by 300 nM CCh (IC 50 = 0.23 ± 0.08 μM, n = 5).
Tamoxifen inhibits Kir3.1/3.4 channels in HEK cells and I KACh in atrial myocytes
Discussion
We demonstrate that tamoxifen, a synthetic nonsteroidal triphenylethylene derivative, which has estrogenic and anti-estrogenic effects, inhibits the inward rectifier potassium channels K ATP (Kir6.2/SUR2A) and K ACh (Kir3.1/3.4) in transfected HEK-293 cells. Tamoxifen also inhibited I KATP and I KACh in atrial myocytes.
The inhibition induced by tamoxifen was concentration-dependent and voltage-independent and occurred slowly (T 1/2 approximately 3.5 min). The IC 50 of tamoxifen on K ATP (Kir6.2/SUR2A) was similar whether the drug was externally applied in the whole-cell configuration (0.33 ± 0.07 μM) or whether it was applied to the internal side of the membrane in the excised inside-out macropatch (0.23 ± 0.04 μM), suggesting that the effect on K ATP (Kir6.2/SUR2A) channels was membrane delimited. The IC 50 of tamoxifen on Kir3.1/3.4 was 0.20 ± 0.04 μM in the whole-cell configuration. During breast cancer treatment, tamoxifen plasma levels are in the range of 0.54 -2.0 μM (21) at usual dose levels, and the levels have been reported to reach up to 1.5 -7.0 μM during high-dose therapy (22) . Therefore, the concentrations of tamoxifen found to significantly inhibit K ATP (Kir6.2/ SUR2A) and K ACh (Kir3.1/3.4) channels are clinically relevant.
Different drugs inhibit the cardiac K ATP and K ACh currents in the plasma membrane of different cells. However, little is known about their mechanisms of action except for sulphonylureas on K ATP and antagonists of muscarinic receptors on K ACh . Molecular studies have revealed that the K ATP channel is an octameric complex of two types of subunits, Kir6.2 and SUR, which co-assemble with 4:4 stoichiometry (11 -13). Kir6.2 forms the pore of the K ATP channel and contains the ATP-inhibitory site, while the sulphonylurea receptor, SUR, acts as a regulatory subunit that endows the channel with sensitivity to sulphonylureas and K ATP -channel openers (15 -17) . Therefore, the effects of drugs that close or open K ATP channels can be mediated through different types of K ATP -channel subunits (23, 24) . Although wild-type K ATP channel requires both types of subunits (Kir6.1 or Kir6.2 and SUR1 or SUR2x) to make a functional channel, a mutant form of Kir6.2 with a C-terminal truncation of 26 or 36 amino acids (Kir6.2ΔC) is capable of independent expression (17). Kir6.2ΔC therefore provides a useful tool for studying the effects of drugs on the pore-forming subunit of the K ATP channel (24, 25) . Our results on Kir6.2ΔC36 show that inhibition by tamoxifen is mediated by interaction of the drug with the Kir6.2 subunit of the K ATP channel, rather than with the regulatory SUR subunit. PIP 2 is an essential signaling phospholipid that is needed for many plasma membrane processes, including the function of ion channels. Activation by PIP 2 is a common feature of all Kir channels; it has been proposed that the channel opens when the negative head charges of PIP 2 interact with positively charged residues in the cytoplasmic domain, near the plasma membrane (26 -28) . It has been suggested that PIP 2 binding causes conformational changes at bundle crossing formed by M2 helix (26) or the G-loop (girdle) structure near the junction between membrane pore and cytoplasmic pore domain (27) , which in turn promotes the open state, and the channel closes when the interaction with PIP 2 is lost. Recent data suggested that the cationic amphiphilic drug tamoxifen may insert into the lipid membrane bilayer and interfere with the interaction between Kir2.x channels and PIP 2 (7) . The characteristics of the tamoxifen inhibition observed in the present work on cardiac K ATP and K ACh channels, like the slow inhibition time course, independence of internal or external drug application, and the voltage-independence, suggest that tamoxifen may interfere with PIP 2 -channel interaction. Inhibition of Kir6.2 currents by tamoxifen was significantly reduced by a single point mutation (C166S). The mutation C166S has been proposed to alter the orientation of the channel's cytoplasmic region in such a way to enhance the R176/ R177-PIP 2 interaction, resulting in bursts of openings (18, 29) . Additional and direct support of the hypothesis that tamoxifen may be interfering with PIP 2 -channel interaction was that continuous application of PIP 2 markedly decreased the inhibition induced by tamoxifen. Thus, our results suggest that membrane PIP 2 is involved in the Kir6.2 current inhibition by tamoxifen. The potency of inhibition on Kir6.2 was similar to that found on Kir2.3; they share a similar low affinity for PIP 2 (10).
Kir3.1 and Kir3.4 subunits were found to encode a heterotetrameric channel with similar electrophysiological properties and atrial distribution as the K ACh channel. The direct binding of G protein βγ subunit (Gβγ) of G i/o proteins to the N-and C-termini of Kir3.1/3.4 channel has been demonstrated to be required for stimulation of channel activity (14, 30, 31) . In 1998, Sui and coworkers showed that the Gβγ activation of the Kir3.1/3.4 channel required the presence of PIP 2 , suggesting a functional dependence of G-protein signaling on membrane phospholipids (32). Kir3.1 and 3.4 channels have a low affinity for PIP 2 and thus are amenable to a high level of modulation. According to our hypothesis, the sensitivity to tamoxifen and inhibition characteristics in Kir3.1/3.4 (I KACh ) may at least be similar to those of Kir2.3 and Kir6.2. We found that the IC 50 for tamoxifen inhibition of Kir3.1/3.4 channels (constitutively activated) expressed in HEK-293 cells and I KACh of atrial myocytes were similar to those found on Kir2.3 and Kir6.2 channels. These results, permit us to suppose that tamoxifen interferes with the PIP 2 -channel interaction on different Kir channels with a low homology and different biophysical characteristics (10) . However, more direct evidence for the interference of tamoxifen on Kir3.1/3.4 channel-PIP 2 interaction is necessary.
Due to integration with the cellular energetic network, K ATP channels adjust cardiomyocyte membrane excitability and produce shortening of the cardiac action potential duration, limiting intracellular calcium loading under conditions of increased demand and high-cardiac performance. Initial evidence suggested that the surface or sarcolemmal K ATP (sarcK ATP ) channel triggered or mediated the cardioprotective effects of ischemic or myocardial preconditioning (IPC). IPC is a phenomenon whereby brief periods of ischemia have been shown to protect the myocardium against a more sustained ischemic insult. The result of IPC may be manifest as a marked reduction in infarct size, myocardial stunning, or incidence of cardiac arrhythmias. Therefore, inhibition of the sarcK ATP channels by tamoxifen may result in poor recovery following coronary hypoperfusion and compromise the protective benefits of ischemic preconditioning.
On the other hand, it has been suggested that the activation of sarcK ATP channels promote arrhythmias, particularly in the setting of acute myocardial ischemia (33) . Since K ATP -channel inhibition is thought to be important in suppression of malignant arrhythmias induced by ischemia, it is tempting to surmise that tamoxifen might be effective in terminating those arrhythmias.
Vagally released ACh stimulates M 2 -type muscarinic receptors and activates the atrial ACh regulated potassium current I KACh , which is important in cardiac parasympathetic regulation. A constitutive form of I KACh , named I KH , also permeated by Kir3 subunits, is increased by β-adrenergic stimulation and during chronic atrial fibrillation (AF) (34 -36) . Increased activity of I KACh has been found to contribute to induction or perpetuation of AF. The increase in I K1 and/or the activation of ACh/adenosine-gated current could stabilize and accelerate rotors (37 -39) . A greater abundance of Kir3.x channels and higher I KACh density in the left atrium compared to the right atrium may contribute to enhanced frequencies and rotor dynamics (40) . Blockade of I KACh may represent a therapeutic target in AF. On the other hand, the inhibitory effects of tamoxifen on I KACh may impair the parasympathetic cardiac control.
